Interview: UCB Sees Bimekizumab As Good Long-Term Bet
UCB immunology chief Emmanuel Caeymaex tells Scrip that despite intense competition, the dual neutralization approach of bimekizumab in inhibiting both interleukin-17A and IL-17F could result in a treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis that may produce faster and more durable clinical improvements than the drugs already on the market.
You may also be interested in...
AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.
Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.